Physician profile
Rade Tomic
NPI 1548377658
$70,304.84
in general payments reported to CMS, 2019-2025
12 companies · $96.83 in 2025
The $96.83 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,615 · 2021: $8,444 · 2022: $18K · 2023: $14K · 2024: $174 · 2025: $96.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,480 · Consulting Fee: $5,760 · Travel and Lodging: $1,058 · Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,480.00 |
| Consulting Fee | $5,760.00 |
| Travel and Lodging | $1,058.16 |
| Food and Beverage | $601.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $69,924.59 | 2019-2024 | Ofev |
| United Therapeutics Corporation | $225.69 | 2023-2025 | Steen Solution, Steen Solution, Tyvaso |
| Genentech USA, INC. | $47.95 | 2020 | |
| La Jolla Pharmaceutical Company | $38.07 | 2023 | Giapreza |
| Glaxosmithkline, LLC. | $20.43 | 2020 | |
| Insmed, INC. | $16.24 | 2020 | |
| Kamada Ltd. | $16.01 | 2025 | |
| Mayne Pharma Commercial LLC | $15.86 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rade Tomic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.